Aarti Drugs Limited
Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate, Ground Floor, Plot No. 109-D, Road No. 29, Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2026-27/10
May 16, 2026

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE CODE: 524348

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
“Exchange Plaza”, Plot No. C/1,
G Block Bandra - Kurla Complex,
Bandra (East), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sub: Press Release on Q4 & FY26 Business & Financial Performance.

Please find attached herewith press release on Q4 & FY26 Business & Financial Performance.

Kindly take the same on record.

Thanking you,

Yours faithfully,
FOR AARTI DRUGS LIMITED

RUSHIKESH VIVEK DEOLE

RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M. No.: F12932

Aarti Drugs Ltd.

Q4 & FY26 Business & Financial Performance

Mumbai, 16th May 2026

Aarti Drugs Limited (Aarti Drugs) (NSE: AARTIDRUGS; BSE:524348), a Mumbai based diversified and fully integrated pharmaceutical company, with interests in Active Pharmaceutical Ingredients (API), Formulation, Specialty Chemicals and Intermediates announced its audited Financial Results for the Quarter and Financial Year ended 31st March 2026.

Consolidated Financial Highlights

Particulars (In Rs Crores)	Q4 FY26	Q4 FY25	YoY	Q3 FY26	QoQ	FY26	FY25	YoY
Revenue	**721.1**	**678.6**	**6%**	**602.9**	**20%**	**2,567.7**	**2,403.4**	**7%**
Gross Profit#	270.7	241.7	12%	216.3	25%	949.0	861.3	10%
EBITDA*	**96.6**	**95.2**	**1%**	**56.3**	**72%**	**311.6**	**303.5**	**3%**
EBITDA Margin %	**13.4%**	**14.0%**	***-60 bps***	**9.3%**	***410 bps***	**12.1%**	**12.6%**	***-50 bps***
Profit Before Tax (PBT)*	70.4	71.1	-1%	29.0	142%	210.9	211.8	0%
Profit After Tax (PAT)	**55.3**	**62.8**	**-12%**	**40.5**	**36%**	**194.9**	**168.2**	**16%**
PAT Margin %	**7.7%**	**9.2%**	***-160 bps***	**6.7%**	***100 bps***	**7.6%**	**7.0%**	***60 bps***
EPS (in ₹)	6.05	6.90		4.44		21.36	18.44	

[1]EBITDA includes other income

[2] Total Revenue, EBITDA and PAT exclude Rs.11.34 crore of interest income on IT refunds receivable from the Income Tax Department for FY25

[3] Q3 & FY26 tax figure includes IT Tax refund of Rs.16.38 crores

Consolidated Financial Highlights – Q4 FY26

- **Revenue** stood at Rs. 721.1 crore as compared to Rs. 678.6 crore in Q4 FY25 and Rs. 602.9 crore in Q3 FY26, reflecting a growth of 6% YoY and 20% QoQ respectively
- **EBITDA** stood at Rs. 96.6 crore versus Rs. 95.2 crore in Q4 FY25 and Rs. 56.3 crore in Q3 FY26, flat YoY and a growth of 72% QoQ. **EBITDA margin** stood at 13.4%
- **PAT** stood at Rs. 55.3 crore as compared to Rs. 62.8 crore in Q4 FY25 and Rs. 40.5 crore in Q3 FY26, a degrowth of 12% YoY and up 36% QoQ. **PAT margin** translated to 7.7% for Q4 FY26

Consolidated Financial Highlights – FY26

- **Revenue** stood at Rs. 2,567.7 crore as compared to Rs. 2,403.4 crore in FY25, reflecting a growth of 7% YoY
- **EBITDA** stood at Rs. 311.6 crore versus Rs. 303.5 crore in FY25, up 3% YoY, with **EBITDA margin** at 12.1%
- **PAT** stood at Rs. 194.9 crore as compared to Rs. 168.2 crore in Q4 FY25, up 16% YoY, translating to **a PAT margin** of 7.6%

Segmental Performance Update

Particulars (In Rs. Crores)	Q4 FY26	Q4 FY25	YoY	Q3 FY26	QoQ	FY26	FY25	YoY
API	**551.0**	553.1	0%	454.3	21%	**1,979.4**	1,938.4	2%
Formulations	**92.0**	64.8	42%	76.4	20%	**331.2**	248.9	33%
Specialty Chemicals	**56.8**	39.0	46%	51.1	11%	**178.3**	130.0	37%
Intermediates & Others	**20.5**	19.8	3%	19.9	3%	**76.4**	69.4	10%

Standalone[3] Business Highlights – Q4 FY26

- Revenue stood at Rs. 631.7 crores vs. Rs. 623.0 crores in Q4 FY25
- Standalone business contributed 88% to the consolidated revenue
- 63% of the standalone revenue came from the domestic market and 37% from the exports market
- Domestic revenue grew 7% YoY and export revenue declined by 7% YoY
- Within the API business, the anti-biotic therapeutic category contributed 37.8%, anti-protozoal 19.6%, anti-inflammatory 11.9%, anti-diabetic 15.0%, antifungal 10.0% and the rest contributed 5.7% to total API sales

Formulation[3] Segment Highlights

- Revenue from formulations stood at Rs. 91.3 crore compared to Rs. 64.8 crore in Q4 FY25, up 41% YoY. Exports contributed 69% to this revenue
- For FY26, formulation revenue was Rs. 330.5 crore compared to Rs. 284.9 crore in FY25, up 16%, with exports accounting for 65% of total formulation sales

[3]Includes other income

Commenting on the same, Mr. Adhish Patil, CFO & COO, Aarti Drugs Limited said,

"FY26 marked an important transition year for Aarti Drugs Limited, as the Company progressed through a major investment and commissioning cycle while navigating a challenging industry environment. Despite persistent macroeconomic headwinds, pricing pressure in select API segments, and elevated raw material volatility, our core business delivered a strong sequential recovery during Q4 FY26 supported by operational scale-up of the Sayakha facility, improving export traction and a better product mix.

Total revenue for Q4FY26 stood at Rs. 721.1 crore, reflecting growth of 6% YoY. EBITDA remained flat YoY to Rs. 96.6 crore, with margin at 13.4%, a decline of 60 bps. The year's profitability remained impacted by two key factors — start-up losses associated with the new facilities, and continued weakness in the domestic antibiotics market.

On a sequential basis, however, performance improved sharply, with revenue and EBITDA rising 20% and 72% respectively, and margins expanding by 410 basis points compared to the previous quarter. This was primarily due to the strong execution progress in our Sayakha facility, which achieved a milestone run-rate of ~1,000 tonnes per month in March 2026. While the scale-up trajectory could have been faster, temporary ammonia shortages impacted production. Nevertheless, the project has now entered a more stable operating phase and is expected to progressively enhance margin resilience and backward integration benefits going forward.

We are also encouraged by the continued improvement in our business mix. Regulated market contribution increased from 66% in FY25 to 73% in FY26, while exports contribution rose from 35% to 38% over the same period. This shift toward regulated and export-oriented business continues to support margin quality and earnings stability. Diversification initiatives also gained momentum during the year, with the Formulations and Specialty Chemicals segments growing 33% and 37% YoY respectively.

From an industry perspective, FY26 witnessed sustained pressure on API realizations, especially during the first half of the year. However, pricing trends began stabilizing from September 2025 onwards, with the recovery trajectory strengthening further during Q4 FY26. At the same time, the sharp increase in key raw material prices and logistics costs — exacerbated by supply chain disruptions arising from geopolitical tensions in West Asia — created additional cost pressures across the industry. Despite these challenges, the Company *was able to partially offset cost inflation through calibrated price increases and improved product mix across its core portfolio.*

The Company's broad product basket, diversified customer base, and increasing share of regulated market business continue to mitigate concentration risks while improving business resilience. Regulatory filings and approvals across the EU and US markets remain a strategic priority, as these markets offer significant realization and margin upside for several existing products. The foundations built over the last few years — including backward integration, expanded regulatory approvals, formulations capability, and specialty product development — position the Company favourably for a meaningful improvement in profitability and return ratios over FY27 and beyond."

About Aarti Drugs Limited

Aarti Drugs Limited was established in the year 1984 and forms part of $6 Billion Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations. The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and produces Formulations with its wholly-owned subsidiary-Pinnacle Life Science Private Limited. The Company have total 14 manufacturing facilities out of which 10 manufacturing facilities are in Maharashtra, 3 Manufacturing facilities in Gujarat and 1 Manufacturing facility of Pinnacle is located at Himachal Pradesh. Products under APIs include Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotinate etc.

For more information, please visit http://www.aartidrugs.com/

For more information, please contact

Company:	Investor Relations (IR)
Aarti Drugs Limited	**Strategic Growth Advisors Pvt. Ltd.**
Aarti Drugs Ltd.	SGA Strategic Growth Advisors
CIN: L37060MH1984PLC055433	CIN: U74140MH2010PTC204285
Mr. Rushikesh Deole	**Mr. Deven Dhruva / Ms. Krisha Shrimankar**
investorrelations@aartidrugs.com	deven.dhruva@sgapl.net / krisha.shrimankar@sgapl.net
+91 22 24048199	+91 98333 73300 / +91 87797 99281
http://www.aartidrugs.com/	www.sgapl.net